LY294002, a PI3K inhibitor, eliminates the role of NCAPG in promoting HCC cell proliferation, while 740Y-P, a PI3K activator, resists the effects of FOXO6 knockdown on the cytotoxicity and glycolysis of paclitaxel in HCC cells (15, 122). The gene discussed is FOXO6; the disease is hepatocellular carcinoma.